Yourgene Health UK Ltd, a wholly-owned subsidiary of Novacyt, has won the tender from the South West London Procurement Partnership for the supply of non-invasive prenatal tests.
Yourgene Health UK Ltd, a subsidiary of Novacyt S.A., has won the competitive tender issued by St George's University Hospitals NHS Foundation Trust (London) for the supply of NIPT using the IONA® Nx NIPT Workflow (CE-IVD). The contract has an initial duration of two years starting from December 2025, with an option for an additional two-year extension. This award represents a continuation of existing activities for the Company, which had signed its first contract with St George's on March 23, 2015.
Ongoing Collaboration and Implementation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Since 2015, St George's has been using the IONA® Nx test under the St George's Antenatal Fetal Evaluation (SAFE) brand, a collaboration between the Fetal Medicine Unit and the Genomics Service at St George. The SAFE test provides NIPTs to about one-third of the maternity services population of the NHS in England and is also offered privately at St George's Hospital. The IONA® Nx NIPT Workflow product is an in vitro diagnostic device for prenatal screening of Down (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes, in line with the recommendations of the UK National Screening Committee and the requirements of NHS England.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2025
Key reported figures
Revenue: 20 MGBP
EBITDA: -7,8 MGBP
Net income: -22,9 MGBP
Outlook / guidance
Management commentary: Nos perspectives pour l'exercice 26 semblent solides, avec un objectif de croissance du chiffre d'affaires à deux chiffres d'une année sur l'autre et la poursuite de notre trajectoire vers une rentabilité de l'EBITDA.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
